IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
|
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [21] PHARMACOKINETIC PROFILE OF CEFODIZIME
    BROCKMEIER, D
    DAGROSA, EE
    INFECTION, 1992, 20 : S14 - S17
  • [22] Pharmacokinetic Profile of Zafirlukast
    P. N. Richard Dekhuijzen
    Peter P. Koopmans
    Clinical Pharmacokinetics, 2002, 41 : 105 - 114
  • [23] PHARMACOKINETIC PROFILE OF ENCAINIDE
    TURGEON, J
    RODEN, DM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (06) : 692 - 694
  • [24] THE PHARMACOKINETIC PROFILE OF AMLODIPINE
    ABERNETHY, DR
    AMERICAN HEART JOURNAL, 1989, 118 (05) : 1100 - 1103
  • [25] PHARMACOKINETIC PROFILE OF DIAMIDFOS IN RATS
    SAUERHOFF, MW
    HEESCHEN, JP
    NYQUIST, RA
    BRAUN, WH
    FOOD AND COSMETICS TOXICOLOGY, 1976, 14 (05): : 401 - 408
  • [26] PHARMACOKINETIC PROFILE OF PYRAZINOBUTAZONE IN MAN
    BRUCHHAUSEN, VV
    LOHMANN, H
    OSVATH, J
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1978, 28-2 (12): : 2337 - 2343
  • [27] PHARMACOKINETIC PROFILE OF PENTACHLOROPHENOL IN MONKEYS
    BRAUN, WH
    SAUERHOFF, MW
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1976, 38 (03) : 525 - 533
  • [28] Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
    Li, Yanjun
    Theuretzbacher, Ursula
    Clancy, Cornelius J.
    Nguyen, M. Hong
    Derendorf, Hartmut
    CLINICAL PHARMACOKINETICS, 2010, 49 (06) : 379 - 396
  • [29] PHARMACOKINETIC PROFILE OF CEFIXIME IN MAN
    FAULKNER, RD
    YACOBI, A
    BARONE, JS
    KAPLAN, SA
    SILBER, BM
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (10) : 963 - 970
  • [30] A PHARMACOKINETIC PROFILE OF NIZATIDINE IN MAN
    CALLAGHAN, JT
    BERGSTROM, RF
    RUBIN, A
    CHERNISH, S
    CRABTREE, R
    KNADLER, MP
    OBERMEYER, B
    OFFEN, WW
    SCHNECK, DW
    ARONOFF, G
    LASSETER, KC
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1987, 22 : 9 - 17